NEW YORK (360Dx) – The US Food and Drug Administration has released a new draft guidance document on applying for Clinical Laboratory Improvement Amendment waivers, including recommendations for making the dual CLIA waiver and 510(k) clearance pathway less burdensome.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.